Maxigen Biotech Inc.(TW:1783)
NT$36.00+0.75 (+2.13%)
TW:1783
Maxigen Biotech Inc. financials statements
NT$36.00
At close:+0.75 (+2.13%)
Maxigen Biotech Inc. (1783) Ratios
Maxigen Biotech Inc. Ratios
TW:1783's free cash flow for Q2 2026 was NT$57.74M. For the 2026 fiscal year, TW:1783's free cash flow was decreased by NT$-17.01M and operating cash flow was NT$74.75M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.21 | 4.03 | 4.72 | 6.56 | 6.75 |
| Quick Ratio | 2.93 | 3.67 | 4.07 | 6.06 | 6.07 |
| Cash Ratio | 1.65 | 3.10 | 3.28 | 5.22 | 4.42 |
| Solvency Ratio | 0.84 | 1.05 | 1.47 | 1.11 | 0.98 |
| Operating Cash Flow Ratio | 0.83 | 1.45 | 1.30 | 1.77 | 1.01 |
| Short-Term Operating Cash Flow Coverage | 2.86 | 0.00 | 3424.00 | 0.00 | 1175.93 |
| Net Current Asset Value | NT$ 765.92M | NT$ 622.97M | NT$ 487.68M | NT$ 841.18M | NT$ 660.09M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.00 | 0.00 | 0.00 | 0.01 |
| Debt-to-Equity Ratio | 0.07 | 0.00 | 0.00 | 0.00 | 0.01 |
| Debt-to-Capital Ratio | 0.06 | 0.00 | 0.00 | 0.00 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.23 | 1.15 | 1.10 | 1.12 | 1.11 |
| Debt Service Coverage Ratio | 2.50 | 0.00 | 2995.58 | 2486.09 | 407.99 |
| Interest Coverage Ratio | 6070.74 | 0.00 | 0.00 | 2508.29 | 513.70 |
| Debt to Market Cap | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.13 | 0.00 | 0.00 | 0.00 | 0.12 |
| Net Debt to EBITDA | -1.62 | -2.89 | -2.43 | -4.05 | -3.86 |
| Profitability Margins | |||||
| Gross Profit Margin | 69.46% | 71.01% | 68.17% | 61.88% | 50.98% |
| EBIT Margin | 32.17% | 28.56% | 24.12% | 27.44% | 19.08% |
| EBITDA Margin | 36.13% | 32.53% | 28.47% | 32.33% | 25.50% |
| Operating Profit Margin | 32.17% | 28.56% | 24.09% | 28.22% | 19.67% |
| Pretax Profit Margin | 37.57% | 33.14% | 31.05% | 27.43% | 19.04% |
| Net Profit Margin | 32.69% | 27.94% | 26.66% | 23.06% | 17.12% |
| Continuous Operations Profit Margin | 32.69% | 27.94% | 26.66% | 23.06% | 17.12% |
| Net Income Per EBT | 87.02% | 84.31% | 85.86% | 84.09% | 89.95% |
| EBT Per EBIT | 116.80% | 116.03% | 128.89% | 97.20% | 96.80% |
| Return on Assets (ROA) | 14.01% | 12.02% | 11.11% | 9.63% | 6.93% |
| Return on Equity (ROE) | 17.25% | 13.83% | 12.18% | 10.76% | 7.68% |
| Return on Capital Employed (ROCE) | 16.91% | 14.12% | 11.01% | 13.16% | 8.76% |
| Return on Invested Capital (ROIC) | 13.81% | 11.91% | 9.45% | 11.06% | 7.86% |
| Return on Tangible Assets | 14.02% | 12.02% | 11.11% | 9.64% | 6.94% |
| Earnings Yield | 6.92% | 4.36% | 3.84% | 3.45% | 2.33% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.14 | 6.55 | 6.41 | 6.04 | 4.48 |
| Payables Turnover | 2.85 | 3.95 | 11.57 | 6.41 | 6.27 |
| Inventory Turnover | 2.50 | 2.61 | 2.32 | 3.06 | 3.18 |
| Fixed Asset Turnover | 1.83 | 1.58 | 1.47 | 1.39 | 1.10 |
| Asset Turnover | 0.43 | 0.43 | 0.42 | 0.42 | 0.40 |
| Working Capital Turnover Ratio | 1.16 | 1.22 | 0.94 | 0.80 | 1.01 |
| Cash Conversion Cycle | 77.67 | 103.35 | 182.41 | 122.73 | 138.14 |
| Days of Sales Outstanding | 59.45 | 55.72 | 56.95 | 60.43 | 81.56 |
| Days of Inventory Outstanding | 146.08 | 140.09 | 157.02 | 119.23 | 114.84 |
| Days of Payables Outstanding | 127.86 | 92.46 | 31.55 | 56.92 | 58.26 |
| Operating Cycle | 205.53 | 195.81 | 213.96 | 179.66 | 196.40 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3.24 | 3.35 | 1.92 | 3.02 | 1.40 |
| Free Cash Flow Per Share | 2.32 | 2.99 | 1.67 | 2.85 | 1.22 |
| Dividend Paid and CapEx Coverage Ratio | 1.85 | 2.47 | 2.64 | 18.58 | 1.64 |
| Capital Expenditure Coverage Ratio | 3.51 | 9.39 | 7.63 | 18.58 | 7.61 |
| Operating Cash Flow Coverage Ratio | 2.86 | 0.00 | 3424.00 | 0.00 | 12.07 |
| Operating Cash Flow to Sales Ratio | 0.36 | 0.44 | 0.28 | 0.44 | 0.23 |
| Free Cash Flow Yield | 5.41% | 6.11% | 3.45% | 6.29% | 2.71% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 14.46 | 22.98 | 26.02 | 28.90 | 42.80 |
| Price-to-Sales (P/S) Ratio | 4.73 | 6.41 | 6.94 | 6.68 | 7.35 |
| Price-to-Book (P/B) Ratio | 2.49 | 3.17 | 3.17 | 3.11 | 3.30 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 18.48 | 16.37 | 29.01 | 15.90 | 36.85 |
| Price-to-Operating Cash Flow Ratio | 13.22 | 14.62 | 25.20 | 15.04 | 32.01 |
| Price-to-Earnings Growth (PEG) Ratio | 0.37 | 1.58 | 1.41 | 0.58 | 1.30 |
| Enterprise Value Multiple | 11.47 | 16.81 | 21.93 | 16.60 | 24.97 |
| Enterprise Value | 3.36B | 3.72B | 3.88B | 3.24B | 3.26B |
| EV to EBITDA | 11.47 | 16.81 | 21.93 | 16.60 | 24.97 |
| EV to Sales | 4.14 | 5.47 | 6.24 | 5.37 | 6.37 |
| EV to Free Cash Flow | 16.19 | 13.97 | 26.11 | 12.78 | 31.92 |
| EV to Operating Cash Flow | 11.58 | 12.48 | 22.69 | 12.09 | 27.73 |
| Tangible Book Value Per Share | 17.15 | 15.43 | 15.26 | 14.56 | 13.61 |
| Shareholders’ Equity Per Share | 17.15 | 15.43 | 15.27 | 14.57 | 13.63 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.13 | 0.16 | 0.14 | 0.16 | 0.10 |
| Revenue Per Share | 9.05 | 7.64 | 6.98 | 6.80 | 6.11 |
| Net Income Per Share | 2.96 | 2.13 | 1.86 | 1.57 | 1.05 |
| Tax Burden | 0.87 | 0.84 | 0.86 | 0.84 | 0.90 |
| Interest Burden | 1.17 | 1.16 | 1.29 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.16 | 0.16 | 0.11 | 0.16 | 0.15 |
| SG&A to Revenue | 0.22 | 0.26 | 0.33 | 0.23 | 0.18 |
| Stock-Based Compensation to Revenue | 0.00 | 0.01 | 0.01 | 0.02 | 0.00 |
| Income Quality | 0.95 | 1.32 | 0.89 | 1.62 | 1.21 |
Currency in TWD
